Online inquiry

IVTScrip™ mRNA-Anti-CD38, CD38-Attenukine(Cap 1, Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ5346MR)

This product GTTS-WQ5346MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & Pseudo-UTP. It ecodes the monoclonal antibody that targets CD38 gene. The antibody can be applied in Multiple myeloma (MM) research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_001775.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 952
UniProt ID P28907
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD38, CD38-Attenukine(Cap 1, Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ5346MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ15817MR IVTScrip™ mRNA-Anti-CD3E&IL3RA, XmAb14045(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA XmAb14045
GTTS-WQ10469MR IVTScrip™ mRNA-Anti-SOST, LY2541546(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA LY2541546
GTTS-WQ14643MR IVTScrip™ mRNA-Anti-DLL3, SC0001-SCX(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA SC0001-SCX
GTTS-WQ4296MR IVTScrip™ mRNA-Anti-SNCA, BIIB-054(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA BIIB-054
GTTS-WQ4930MR IVTScrip™ mRNA-Anti-TNFRSF17, C11D5.3 scFv-8A-F9Z CAR(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA C11D5.3 scFv-8A-F9Z CAR
GTTS-WQ6199MR IVTScrip™ mRNA-Anti-CD40, CP-870893(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA CP-870893
GTTS-WQ13170MR IVTScrip™ mRNA-Anti-TNFRSF4, PF-04518600(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA PF-04518600
GTTS-WQ12518MR IVTScrip™ mRNA-Anti-PDCD1, NPVPDR001(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA NPVPDR001
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW